Retatrutide

Advanced Fermentation Platforms
Professional CDMO Service
GMP-Compliant Pharmaceutical Purity

Premium API

Retatrutide API

Retatrutide is an experimental drug for obesity, it is a triple glucagon hormone receptor agonist (including GLP-1, GIP, GCGR receptors). This combination contributes to the powerful edge over other medications with just one or two pathways. It demonstrates greater efficacy in weight loss and metabolic improvements, compared to both semaglutide and tirzepatide.

Premium API

Retatrutide

Peptide Name: Retatrutide
CAS Number: 2381089-83-2
Formula: C_₂₂₁H_₃₄₂N_₄₆O_₆₈
Molecular Weight: 4731g/mol
Sequence: YAQGT FTSDY SILLD KKAQA AFIEY LLEGG PSSGA PPPS
Purity: 98%
Type: Drug Peptides, Synthetic peptide

Premium API

Retatrutide Description

Retatrutide is a triple agonist, it targets the glucagon receptor, gastric inhibitory polypeptides, glucagon-like peptide-1. Retatrutide has complex mechanism of the synergistic interaction among these receptors, contributes to increased insulin secretion, improved glucose homeostasis, and refined appetite modulation. It demonstrates significant efficacy in body weight-less and glycemic control outcomes. Additionally, retatrutide also shows functions in mitigating cardiovascular risk factors and addressing metabolic dysfunction-associated steatotic liver disease.

Clinical Trials

Retatrutide in clinical trials have groundbreaking results, it is the transformative option for managing diabetes and promoting weight loss.

Body weight reduction of retatrutide surpass the effectiveness of many existing treatments. The level of weight loss is significant for patients with obesity, it sets the new standard in obesity treatment.
HbA1c levels improvement is another critical outcome in the trials, retatrutide has the medication effectiveness in managing long-term glucose control.
In addition, trials show better metabolic health overall, and improved lipid profiles. This not only enhances diabetes managements, but also reduce the likelihood of heart diseases.

Key Benefits

The triple receptor action of retatrutide provide significant benefits over conventional medications in phase 2 trials of Eli Lilly and Company.

Broader Action Mechanism: The multiple-receptor approach provides comprehensive metabolic benefits, while traditional medications only target the single pathway.
Better Weight-Loss Outcomes: Retatrutide provides high level of weight reduction over traditional treatments, it is the valuable option for patients with obesity-related health issues.
Reduced Medication Burden: simplified regimen can address multiple health concerns with one treatment in high efficiency.

Retatrutide Reference

Retatrutide Mechanism

Retatrutide has multi-receptor mechanism to address diabetes and obesity simultaneouly, it tri-receptor action provides a more comprehensive effect.
Blood sugar regulation: Retatrutide can maintain consistent blood sugar levels throughout the day by activation of GLP-1 and GIP receptors.
Weight Loss: activation of glucagon receptor can boost fat metabolism and curbs appetite.
Cardiovascular Benefit: retatrutide can reduce cardiovascular risk associated with type 2 diabetes, and enhance its comprehensive metabolic treatment.

Retatrutide Reference

Potential Side Effect

Like any medication, retatrutide may cause side effects, though many of them are mild and manageable:

Nausea & Vomiting: This is common as the body adjustments, avoiding high-fat foods and eating less meals will minimize these symptoms.
Diarrhea & Constipation: Gastrointestinal issues are temporary, incorporating fiber into the diet will alleviate discomfort.
Fatigue: Mild tiredness may occur during the initial treatment phase, light exercise and adequate rest will mitigate this effect.
Hypoglucemia: It is rare to occur low blood sugar levels once combine with other diabetes medications.